• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersThe Capsule

India locks down in the midst of coronavirus

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
March 24, 2020, 9:18 PM ET

Hello, readers.

A nation with 1.3 billion people has now ordered a lockdown over the coronavirus outbreak.

Indian Prime Minister Narendra Modi is mandating a three-week (at minimum) national lockdown after several Indian states had already implemented such measures. In a press conference, he played up the importance of social distancing, especially in a country with such heavy population density.

“You have seen the worldwide situations arising from the coronavirus pandemic in the news. You have also seen how the most powerful nations have become helpless in the face of this pandemic,” Modi said on Tuesday, according to CNN, warning that “many families will be destroyed forever” if drastic measures aren’t enacted.

Those measures resemble what some states and cities in the U.S. Have enacted, including encouraging people to limit their contact with the outside world other than essential utility, grocery, and medical services.

So there you have it—the second most populous country in the world, is shutting down.

Read on for the day’s news.

Sy Mukherjee
[email protected]
@the_sy_guy

DIGITAL HEALTH

A.I. Struggles under the weight of coronavirus. My colleague Jeremy Kahn explains, eloquently, how the coronavirus crisis "is providing a real-world test of how robust many companies’ new-fangled A.I. Systems really are." This is one of those moments where the rubber meets the road. And the artificial intelligence "rubber" really only came onto the scene in the past five years. That has implications for everything from predicting financial trends to the intricacies of the food supply chain. (Coins2Day)

INDICATIONS

Novartis gets some good news on its spinal muscular dystrophy drug.  Novartis' landmark spinal muscular dystrophy drug Zolgensma is (according to the company, anyways) still racking up positive clinical trial results even though those very studies are on hold. Zolgensma is a bit of a controversial therapy (for more on that, head over here) but has the distinction of being the first gene therapy ever approved in the U.S. Novartis is trying to expand the treatment's reach into other forms of the degenerative, inherited disorder.

THE BIG PICTURE

The specter of a looming recession. Just how bad might the economic repercussions of coronavirus be? According to data Moody's Analytics provided to Coins2Day, there could five to six million job losses in March alone. “This is cataclysmic. I can’t think of a darker word. It’s Armageddon if lawmakers don’t come up with support [for businesses and households] in the next couple days,” Mark Zandi, chief economist of Moody’s Analytics, told Coins2Day. (Coins2Day)

REQUIRED READING

A first responder spouse on when, not if, the coronavirus strikes, by Kristen Bellstrom

Yale's most popular class is now available online for free, by Ellen McGirt

17 companies that are hiring during the coronavirus crisis, by Chris Morris

Sign up for other Coins2Day newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.